244 related articles for article (PubMed ID: 26213845)
21. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
[TBL] [Abstract][Full Text] [Related]
22. [eIF3a gene polymorphism and chemo-sensitivity to platinum-based drugs in ovarian cancer].
Zhang C; Zhang S; Liu Y; Tian Y; Li X; Zhang Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Jun; 40(6):617-22. PubMed ID: 26164510
[TBL] [Abstract][Full Text] [Related]
23. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
24. Role of eukaryotic translation initiation factors 3a in hypoxia-induced right ventricular remodeling of rats.
Li WQ; Li XH; Wu YH; Du J; Wang AP; Li D; Li YJ
Life Sci; 2016 Jan; 144():61-8. PubMed ID: 26612348
[TBL] [Abstract][Full Text] [Related]
25. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
26. [Correlation between eIF3a and HE4 expression and ovarian cancer].
Wang J; Luo C; Wang Y; Tang Y; Fang K; Zeng L; Zhang Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Dec; 39(12):1240-5. PubMed ID: 25544161
[TBL] [Abstract][Full Text] [Related]
27. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
28. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
Yunmbam MK; Guo Y; Miller MR; Yu JJ
Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
[TBL] [Abstract][Full Text] [Related]
29. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
Qi C; Zhang QH; Li JX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
[TBL] [Abstract][Full Text] [Related]
30. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
31. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
32. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
33. MiR-200c and HuR in ovarian cancer.
Prislei S; Martinelli E; Mariani M; Raspaglio G; Sieber S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
BMC Cancer; 2013 Feb; 13():72. PubMed ID: 23394580
[TBL] [Abstract][Full Text] [Related]
34. Eukaryotic Translation Initiation Factor 3a (eIF3a) Promotes Cell Proliferation and Motility in Pancreatic Cancer.
Wang SQ; Liu Y; Yao MY; Jin J
J Korean Med Sci; 2016 Oct; 31(10):1586-94. PubMed ID: 27550487
[TBL] [Abstract][Full Text] [Related]
35. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
36. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
38. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
39. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.
Sun KX; Jiao JW; Chen S; Liu BL; Zhao Y
J Ovarian Res; 2015 Dec; 8():80. PubMed ID: 26626440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
